Richard E Carson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6863997/publications.pdf

Version: 2024-02-01

396 papers 21,667 citations

72 h-index 128 g-index

424 all docs

424 docs citations

424 times ranked 16173 citing authors

#	Article	IF	CITATIONS
1	Feasibility study of PET dynamic imaging of [18F]DHMT for quantification of reactive oxygen species in the myocardium of large animals. Journal of Nuclear Cardiology, 2022, 29, 216-225.	1.4	5
2	Optimized Methodology for Reference Region and Image-Derived Input Function Kinetic Modeling in Preclinical PET. IEEE Transactions on Radiation and Plasma Medical Sciences, 2022, 6, 454-462.	2.7	2
3	Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer ¹¹ C-TASP699. Journal of Nuclear Medicine, 2022, 63, 609-614.	2.8	7
4	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [<scp>¹¹C</scp>] <scp>PBR28</scp> and Machine Learning Analysis. Movement Disorders, 2022, 37, 119-129.	2.2	18
5	Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. Neurobiology of Aging, 2022, 111, 44-53.	1.5	25
6	A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1482-1496.	3.3	16
7	Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory ¹¹ Câ€UCBâ€J positron emission tomography study in humans. Addiction Biology, 2022, 27, e13123.	1.4	16
8	Translational PET Imaging of Spinal Cord Injury with the Serotonin Transporter Tracer $[11C]$ AFM. Molecular Imaging and Biology, 2022, , 1.	1.3	O
9	Characterization in nonhuman primates of (R)-[18F]OF-Me-NB1 and (S)-[18F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	3.3	8
10	Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates: $\langle i \rangle (R) \langle i \rangle - [\langle sup \rangle 11 \langle sup \rangle C] NR2B-Me, \langle i \rangle (R) \langle i \rangle - [\langle sup \rangle 18 \langle sup \rangle F] of-NB1, and \langle i \rangle (S) \langle i \rangle - [\langle sup \rangle 18 \langle sup \rangle F] of-NB1. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1398-1409.$	2.4	7
11	Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [¹¹ C]UCBâ€. Alzheimer's and Dementia, 2022, 18, 2527-2536.	0.4	55
12	Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry, 2022, 27, 2273-2281.	4.1	25
13	Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates. EJNMMI Research, 2022, 12, 13.	1.1	1
14	PET-BIDS, an extension to the brain imaging data structure for positron emission tomography. Scientific Data, 2022, 9, 65.	2.4	20
15	Multimodal neuroimaging of metabotropic glutamate 5 receptors and functional connectivity in alcohol use disorder. Alcoholism: Clinical and Experimental Research, 2022, , .	1.4	О
16	PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging. Frontiers in Neuroscience, 2022, 16, 787404.	1.4	5
17	Adaptive data-driven motion detection and optimized correction for brain PET. Neurolmage, 2022, 252, 119031.	2.1	8
18	Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET. EJNMMI Physics, 2022, 9, 32.	1.3	3

#	Article	IF	Citations
19	Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET). European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3679-3691.	3.3	4
20	Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Science Translational Medicine, 2022, 14, .	5.8	38
21	Imaging of Synaptic Density in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 60S-67S.	2.8	29
22	Accelerating PET Image Reconstruction with CUDA. , 2022, , .		0
23	Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Molecular Psychiatry, 2021, 26, 3192-3200.	4.1	32
24	Binding of the synaptic vesicle radiotracer [$<$ sup $>$ 11 $<$ /sup $>$ C]UCB-J is unchanged during functional brain activation using a visual stimulation task. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1067-1079.	2.4	28
25	Simplified Quantification of ¹¹ C-UCB-J PET Evaluated in a Large Human Cohort. Journal of Nuclear Medicine, 2021, 62, 418-421.	2.8	19
26	First-in-Human Evaluation of ¹⁸ F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. Journal of Nuclear Medicine, 2021, 62, 561-567.	2.8	60
27	Multimodal investigation of dopamine D2/D3 receptors, default mode network suppression, and cognitive control in cocaine-use disorder. Neuropsychopharmacology, 2021, 46, 316-324.	2.8	14
28	Acute neuroimmune stimulation impairs verbal memory in adults: A PET brain imaging study. Brain, Behavior, and Immunity, 2021, 91, 784-787.	2.0	6
29	Quantification of SV2A Binding in Rodent Brain Using [18F]SynVesT-1 and PET Imaging. Molecular Imaging and Biology, 2021, 23, 372-381.	1.3	20
30	Longitudinal imaging of metabotropic glutamate 5 receptors during early and extended alcohol abstinence. Neuropsychopharmacology, 2021, 46, 380-385.	2.8	7
31	First-in-Human Assessment of $\langle \sup 11 \rangle 11 \langle \sup \rangle C$ -LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. Journal of Nuclear Medicine, 2021, 62, 553-560.	2.8	35
32	PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. Cerebral Cortex, 2021, 31, 2787-2798.	1.6	5
33	Association of Aβ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. Alzheimer's Research and Therapy, 2021, 13, 11.	3.0	53
34	Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1327-1338.	3.3	23
35	Dopamine D2/3 receptor availability in cocaine use disorder individuals with obesity as measured by [11C]PHNO PET. Drug and Alcohol Dependence, 2021, 220, 108514.	1.6	1
36	Comparison of [¹¹ C]UCB-J and [¹⁸ F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2395-2409.	2.4	43

#	Article	IF	Citations
37	Preliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral Therapy. Clinical Infectious Diseases, 2021, 73, 1404-1411.	2.9	25
38	In vivo evidence of lower synaptic vesicle density in schizophrenia. Molecular Psychiatry, 2021, 26, 7690-7698.	4.1	51
39	Generation of synthetic PET images of synaptic density and amyloid from ¹⁸ Fâ€FDG images using deep learning. Medical Physics, 2021, 48, 5115-5129.	1.6	12
40	Multiparametric cardiac 18F-FDG PET in humans: pilot comparison of FDG delivery rate with 82Rb myocardial blood flow. Physics in Medicine and Biology, 2021, 66, 155015.	1.6	3
41	Lower synaptic density is associated with psychiatric and cognitive alterations in obesity. Neuropsychopharmacology, 2021, , .	2.8	7
42	Generation of parametric <i>K</i> _i images for FDG PET using two 5â€min scans. Medical Physics, 2021, 48, 5219-5231.	1.6	16
43	Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis. Neurolmage, 2021, 237, 118167.	2.1	18
44	Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [18F]FPEB PET. NeuroImage, 2021, 238, 118217.	2.1	10
45	Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease. Neurolmage, 2021, 238, 118248.	2.1	17
46	Novel Reversible-Binding PET Ligands for Imaging Monoacylglycerol Lipase Based on the Piperazinyl Azetidine Scaffold. Journal of Medicinal Chemistry, 2021, 64, 14283-14298.	2.9	9
47	Synthesizing Multi-tracer PET Images for Alzheimer's Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial Network. Lecture Notes in Computer Science, 2021, , 34-43.	1.0	6
48	PET Imaging of Synaptic Vesicle Protein 2A. , 2021, , 993-1019.		10
49	Imaging brain cortisol regulation in PTSD with a target for $11\hat{l}^2$ -hydroxysteroid dehydrogenase type 1. Journal of Clinical Investigation, 2021, 131, .	3.9	10
50	Data-driven analysis of kappa opioid receptor binding in major depressive disorder measured by positron emission tomography. Translational Psychiatry, 2021, 11, 602.	2.4	1
51	Quantification of PET infusion studies without true equilibrium: A tissue clearance correction. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 860-874.	2.4	6
52	Parametric Imaging With PET and SPECT. IEEE Transactions on Radiation and Plasma Medical Sciences, 2020, 4, 1-23.	2.7	43
53	First in-human PET study and kinetic evaluation of $[\sup 18 for imaging 11^2-hydroxysteroid dehydrogenase type 1. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 695-704.$	2.4	10
54	Direct List Mode Parametric Reconstruction for Dynamic Cardiac SPECT. IEEE Transactions on Medical Imaging, 2020, 39, 119-128.	5.4	7

#	Article	IF	CITATIONS
55	PET Imaging of Pancreatic Dopamine D ₂ and D ₃ Receptor Density with ¹¹ C-(+)-PHNO in Type 1 Diabetes. Journal of Nuclear Medicine, 2020, 61, 570-576.	2.8	19
56	Atlas-Based Multiorgan Segmentation for Dynamic Abdominal PET. IEEE Transactions on Radiation and Plasma Medical Sciences, 2020, 4, 50-62.	2.7	14
57	Assessment of a white matter reference region for $\sup 11 < \sup C$ -UCB-J PET quantification. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1890-1901.	2.4	77
58	Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRB. International Journal of Obesity, 2020, 44, 964-967.	1.6	18
59	Measuring the effects of ketamine on mGluR5 using [¹⁸ F]FPEB and PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 2254-2264.	2.4	13
60	In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research - Neuroimaging, 2020, 295, 111007.	0.9	17
61	Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [¹¹ C]UCB†positron emission tomography study. Epilepsia, 2020, 61, 2183-2193.	2.6	51
62	[¹¹ C]Methionine and [¹¹ C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. Molecular Imaging, 2020, 19, 153601212096866.	0.7	12
63	The rate of dasotraline brain entry is slow following intravenous administration. Psychopharmacology, 2020, 237, 3435-3446.	1.5	1
64	In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037791.	0.4	1
65	PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037792.	0.4	0
66	The aging rhesus macaque as a potential model for Alzheimer's disease/dementia: An in vivo study of [11 C]PIB, [11 C]UCBâ€j, [18 F]MKâ€6240 and working memory performance. Alzheimer's and Dementia, 2020, 16, e038467.	0.4	0
67	ICAâ€derived sources of synaptic density PET ([11 C]UCBâ€) relate to cognitive impairment severity in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041197.	0.4	3
68	11Câ€PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043584.	0.4	0
69	Association between cerebral amyloid accumulation and synaptic density in Alzheimer's disease: A multitracer PET study. Alzheimer's and Dementia, 2020, 16, e043631.	0.4	0
70	Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044211.	0.4	2
71	Validation of a simplified tissueâ€toâ€reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer's disease using [11 C]UCB†PET. Alzheimer's and Dementia, 2020, 16, e045928.	0.4	1
72	In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimer's and Dementia, 2020, 16, 974-982.	0.4	170

#	Article	IF	CITATIONS
73	PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studies. Nature Communications, 2020, 11, 2360.	5. 8	56
74	Kinetic Modeling and Test–Retest Reproducibility of ¹¹ C-EKAP and ¹¹ C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the κ-Opioid Receptor in Humans. Journal of Nuclear Medicine, 2020, 61, 1636-1642.	2.8	10
75	Body Mass Index and Age Effects on Brain $11\hat{l}^2$ -Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study. Molecular Imaging and Biology, 2020, 22, 1124-1131.	1.3	9
76	Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1576-1585.	2.4	47
77	Synthesis and Preclinical Evaluation of an ¹⁸ F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [¹⁸ F]SynVesT-2. ACS Chemical Neuroscience, 2020, 11, 592-603.	1.7	34
78	Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. Annals of Neurology, 2020, 87, 329-338.	2.8	112
79	PET imaging of mGluR5 in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 15.	3.0	29
80	Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study. Journal of Nuclear Medicine, 2020, 61, 1200-1204.	2.8	8
81	Data-Driven Motion Detection and Event-by-Event Correction for Brain PET: Comparison with Vicra. Journal of Nuclear Medicine, 2020, 61, 1397-1403.	2.8	32
82	Inverse changes in raphe and cortical $5\hat{a}\in HT$ 1B receptor availability after acute tryptophan depletion in healthy human subjects. Synapse, 2020, 74, e22159.	0.6	9
83	Separating dopamine D2 and D3 receptor sources of $[11C]$ -(+)-PHNO binding potential: Independent component analysis of competitive binding. Neurolmage, 2020, 214, 116762.	2.1	9
84	Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand 11C-UCB-J. EJNMMI Research, 2020, 10, 83.	1.1	8
85	Assessment of population-based input functions for Patlak imaging of whole body dynamic 18F-FDG PET. EJNMMI Physics, 2020, 7, 67.	1.3	45
86	Quantitative Cerebral Blood Flow with PET in the 1980s: Going with the Flow (perspective on "Brain) Tj ETQc	2.8	1 /Overlock 10
87	Journal of Nuclear Medicine, 2020, 61, 89S-104S. Reply: $11C$ -(+)-PHNO Trapping Reversibility for Quantitative PET Imaging of \hat{I}^2 -Cell Mass in Patients with Type 1 Diabetes. Journal of Nuclear Medicine, 2020, 61, 1693-1693.	2.8	0
88	In vivo imaging of D2 receptors and corticosteroids predict behavioural responses to captivity stress in a wild bird. Scientific Reports, 2019, 9, 10407.	1.6	3
89	Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2329-2338.	3.3	70
90	Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles. Theranostics, 2019, 9, 6991-7002.	4.6	54

#	Article	IF	Citations
91	S13. IN VIVO EVIDENCE OF REDUCED SYNAPTIC VESICLE DENSITY IN SCHIZOPHRENIA USING [11C] UCB-J PET IMAGING. Schizophrenia Bulletin, 2019, 45, S310-S311.	2.3	0
92	Data-driven voluntary body motion detection and non-rigid event-by-event correction for static and dynamic PET. Physics in Medicine and Biology, 2019, 64, 065002.	1.6	32
93	Human Positron Emission Tomography Neuroimaging. Annual Review of Biomedical Engineering, 2019, 21, 551-581.	5.7	48
94	Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1952-1965.	3.3	38
95	In Vivo Synaptic Density Imaging with $\langle \sup 11 \rangle 11 \langle \sup C-UCB-J $ Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. Journal of Nuclear Medicine, 2019, 60, 1780-1786.	2.8	57
96	142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations. Biological Psychiatry, 2019, 85, S59.	0.7	4
97	Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study. Neuropsychopharmacology, 2019, 44, 1720-1727.	2.8	36
98	In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11490-11495.	3.3	34
99	REGION-SPECIFIC ATROPHY AS MEASURED BY CORTICAL GRAY MATTER VOLUME IS ASSOCIATED WITH BOTH REGIONAL AND TOTAL CORTICAL AMYLOID-BETA BURDEN IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE. American Journal of Geriatric Psychiatry, 2019, 27, S186-S187.	0.6	1
100	Brain-Dedicated Emission Tomography Systems: A Perspective on Requirements for Clinical Research and Clinical Needs in Brain Imaging. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 254-261.	2.7	17
101	Imaging the Enzyme $11\hat{1}^2$ -Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer ^{11} C-AS2471907 in Human Brain. Journal of Nuclear Medicine, 2019, 60, 1140-1146.	2.8	11
102	Event-by-event non-rigid data-driven PET respiratory motion correction methods: comparison of principal component analysis and centroid of distribution. Physics in Medicine and Biology, 2019, 64, 165014.	1.6	11
103	Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. Neuropsychopharmacology, 2019, 44, 1714-1719.	2.8	22
104	A singleâ€center, openâ€label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia, 2019, 60, 958-967.	2.6	45
105	Lower synaptic density is associated with depression severity and network alterations. Nature Communications, 2019, 10, 1529.	5.8	277
106	Evaluation of ¹¹ C-LSN3172176 as a Novel PET Tracer for Imaging M ₁ Muscarinic Acetylcholine Receptors in Nonhuman Primates. Journal of Nuclear Medicine, 2019, 60, 1147-1153.	2.8	17
107	P4â€481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimer's and Dementia, 2019, 15, P1497.	0.4	0
108	ICâ€Pâ€140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTIâ€TRACER STUDY IN HEALTHY A AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P115.	reina r	0

#	Article	IF	Citations
109	F33. In Vivo Brain Imaging of 11beta-Hydroxysteroid Dehydrogenase, a Marker of Cortisol Production, in PTSD. Biological Psychiatry, 2019, 85, S225.	0.7	O
110	Synthesis and <i>in Vivo</i> Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. ACS Chemical Neuroscience, 2019, 10, 1544-1554.	1.7	70
111	Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy. Bulletin of Mathematical Biology, 2019, 81, 3508-3541.	0.9	21
112	Respiratory Motion Compensation for PET/CT with Motion Information Derived from Matched Attenuation-Corrected Gated PET Data. Journal of Nuclear Medicine, 2018, 59, 1480-1486.	2.8	54
113	Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes. Molecular Imaging and Biology, 2018, 20, 835-845.	1.3	24
114	Simplified Quantification and Acquisition Protocol for ¹²³ I-MIBG Dynamic SPECT. Journal of Nuclear Medicine, 2018, 59, 1574-1580.	2.8	5
115	F188. Preliminary Evidence for mGluR5 Dysregulation in Borderline Personality Disorder and Relationship to Suicidal Behavior. Biological Psychiatry, 2018, 83, S312.	0.7	2
116	Age-Related Change in 5-HT ₆ Receptor Availability in Healthy Male Volunteers Measured with ¹¹ C-GSK215083 PET. Journal of Nuclear Medicine, 2018, 59, 1445-1450.	2.8	34
117	Evaluation of PET Brain Radioligands for Imaging Pancreatic \hat{I}^2 -Cell Mass: Potential Utility of 11C-(+)-PHNO. Journal of Nuclear Medicine, 2018, 59, 1249-1254.	2.8	22
118	Investigation of Sub-Centimeter Lung Nodule Quantification for Low-Dose PET. IEEE Transactions on Radiation and Plasma Medical Sciences, 2018, 2, 41-50.	2.7	6
119	Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry, 2018, 84, 413-421.	0.7	43
120	Non-Rigid Event-by-Event Continuous Respiratory Motion Compensated List-Mode Reconstruction for PET. IEEE Transactions on Medical Imaging, 2018, 37, 504-515.	5.4	33
121	Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging. Diabetologia, 2018, 61, 2598-2607.	2.9	18
122	A 3D-printed modular device for imaging the brain of small birds. Journal of Neuroscience Methods, 2018, 293, 183-190.	1.3	6
123	Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand ¹¹ C-BMT-136088 for Lung Imaging in Rhesus Monkeys. Journal of Nuclear Medicine, 2018, 59, 327-333.	2.8	16
124	Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease. Neurobiology of Aging, 2018, 61, 207-214.	1.5	28
125	Cardiacâ€gated parametric images from ⁸² Rb <scp>PET</scp> from dynamic frames and direct 4D reconstruction. Medical Physics, 2018, 45, 639-654.	1.6	9
126	Evaluation of (â€)â€[¹⁸ <scp>F]F</scp> lubatineâ€specific binding: Implications for reference region approaches. Synapse, 2018, 72, e22016.	0.6	7

#	Article	IF	CITATIONS
127	Kinetic evaluation and test–retest reproducibility of [¹¹ C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 2041-2052.	2.4	143
128	P2â€365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P832.	0.4	0
129	P1â€469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P501.	0.4	1
130	ICâ€04â€03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P8.	0.4	0
131	ICâ€Pâ€183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P152.	0.4	O
132	Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials?. American Journal of Geriatric Psychiatry, 2018, 26, S145-S146.	0.6	3
133	F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET. Biological Psychiatry, 2018, 83, S296.	0.7	4
134	F3. Imaging Alpha7 Nicotinic Acetylcholine Receptors in Individuals With PTSD. Biological Psychiatry, 2018, 83, S237-S238.	0.7	0
135	Kappa opioid receptor binding in major depression: A pilot study. Synapse, 2018, 72, e22042.	0.6	26
136	InÂVivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents. JACC Basic To Translational Science, 2018, 3, 378-390.	1.9	46
137	Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurology, 2018, 75, 1215.	4.5	304
138	Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static ¹⁸ F-FDG PET as a function of injected dose. Physics in Medicine and Biology, 2018, 63, 175015.	1.6	17
139	Clinical and scientific value in the pursuit of quantification of beta cells in the pancreas by PET imaging. Diabetologia, 2018, 61, 2671-2673.	2.9	6
140	High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. International Journal of Radiation Oncology Biology Physics, 2018, 102, 174-183.	0.4	36
141	Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2244-2252.	1.8	23
142	Novel Use of Agent 11C-PHNO for Pet CT Imaging of Pancreatic Beta-Cell Mass. Diabetes, 2018, 67, .	0.3	0
143	Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1095-1107.	2.4	31
144	Regional and source-based patterns of [11 C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D 2 and D 3 receptor availability in cocaine-use disorder. NeuroImage, 2017, 148, 343-351.	2.1	32

#	Article	IF	CITATIONS
145	Experimentally reducing corticosterone mitigates rapid captivity effects on behavior, but not body composition, in a wild bird. Hormones and Behavior, 2017, 89, 121-129.	1.0	29
146	PET imaging of $\hat{l}\pm7$ nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1042-1050.	3.3	47
147	Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 449-456.	1.1	47
148	Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements. Molecular Imaging and Biology, 2017, 19, 893-902.	1.3	17
149	PET Imaging for Early Detection of Alzheimer's Disease. PET Clinics, 2017, 12, 329-350.	1.5	44
150	Data-driven event-by-event respiratory motion correction using TOF PET list-mode centroid of distribution. Physics in Medicine and Biology, 2017, 62, 4741-4755.	1.6	44
151	The Search for a Subtype-Selective PET Imaging Agent for the GABA _A Receptor Complex: Evaluation of the Radiotracer [¹¹ C]ADO in Nonhuman Primates. Molecular Imaging, 2017, 16, 153601211773125.	0.7	8
152	Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8390-8395.	3.3	107
153	18. In Vivo Quantification of mGluR5 Availability in Posttraumatic Stress Disorder. Biological Psychiatry, 2017, 81, S8.	0.7	O
154	389. In Vivo Evidence of Lower Synaptic Density in Depression and Associated Mood and Cognitive Deficits: A [11C]UCB-J PET Imaging Study. Biological Psychiatry, 2017, 81, S159.	0.7	3
155	962. In-vivo Evidence of Decreased Synaptic Density in Schizophrenia: A [11C]UCB-J PET Imaging Study. Biological Psychiatry, 2017, 81, S389.	0.7	7
156	Trends in Radiation Medical Sciences: Instrumentation and Imaging Algorithms. IEEE Transactions on Radiation and Plasma Medical Sciences, 2017, 1, 201-205.	2.7	2
157	Direct reconstruction of parametric images for brain PET with event-by-event motion correction: evaluation in two tracers across count levels. Physics in Medicine and Biology, 2017, 62, 5344-5364.	1.6	17
158	InÂvivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [¹¹ C]ABP688 and [¹⁸ F]FPEB. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2716-2727.	2.4	49
159	Quantitative projection of human brain penetration of the H ₃ antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy. Xenobiotica, 2017, 47, 119-126.	0.5	5
160	Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primates. EJNMMI Research, 2017, 7, 59.	1.1	39
161	Accounting for Breathing Pattern Variability in Event-by-Event Respiratory Motion Correction in PET Using Dynamic Internal-External Motion Correlation. , 2017, , .		1
162	Strategies to Improve Direct EM Patlak Reconstructions. , 2017, , .		0

#	Article	IF	Citations
163	GPU-based List-mode Direct Parametric Reconstruction for Dynamic Cardiac SPECT., 2017,,.		1
164	Estradiol modulates neural response to conspecific and heterospecific song in female house sparrows: An in vivo positron emission tomography study. PLoS ONE, 2017, 12, e0182875.	1.1	16
165	Direct EM reconstruction of parametric images from list-mode brain PET using a novel model based on logan graphical analysis. , 2016, , .		3
166	Nicotine and Nicotine Abstinence Do Not Interfere with GABA _A Receptor Neuroadaptations During Alcohol Abstinence. Alcoholism: Clinical and Experimental Research, 2016, 40, 698-705.	1.4	5
167	Comparative evaluation of two glycine transporter 1 radiotracers [11C]GSK931145 and [18F]MK-6577 in baboons. Synapse, 2016, 70, 112-120.	0.6	4
168	Quantification of myocardial blood flow with 82Rb: Validation with 15O-water using time-of-flight and point-spread-function modeling. EJNMMI Research, 2016, 6, 68.	1.1	34
169	Preclinical Evaluation of ¹⁸ F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme. Journal of Nuclear Medicine, 2016, 57, 1448-1453.	2.8	13
170	Event-by-Event Continuous Respiratory Motion Correction for Dynamic PET Imaging. Journal of Nuclear Medicine, 2016, 57, 1084-1090.	2.8	39
171	Quantitative Analysis of Dynamic ¹²³ I-mIBG SPECT Imaging Data in Healthy Humans with a Population-Based Metabolite Correction Method. Journal of Nuclear Medicine, 2016, 57, 1226-1232.	2.8	17
172	First-in-Human Assessment of the Novel PDE2A PET Radiotracer ¹⁸ F-PF-05270430. Journal of Nuclear Medicine, 2016, 57, 1388-1395.	2.8	27
173	Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18 F-FP-DTBZ in baboons. Nuclear Medicine and Biology, 2016, 43, 743-751.	0.3	20
174	Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO. Neuropsychopharmacology, 2016, 41, 3042-3050.	2.8	47
175	Brivaracetam, a selective highâ€affinity synaptic vesicle protein 2A (<scp>SV</scp> 2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia, 2016, 57, 201-209.	2.6	130
176	Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology, 2016, 233, 3503-3512.	1.5	101
177	Imaging synaptic density in the living human brain. Science Translational Medicine, 2016, 8, 348ra96.	5.8	343
178	Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteers. NeuroImage, 2016, 130, 241-247.	2.1	43
179	Receptor Occupancy of the Â-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 260-266.	1.3	47
180	Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biological Psychiatry, 2016, 79, 997-1005.	0.7	83

#	Article	IF	CITATIONS
181	OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. Journal of Affective Disorders, 2016, 196, 87-96.	2.0	38
182	Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 60-67.	1.1	135
183	Synthesis and Preclinical Evaluation of ^{11 < sup>C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. Journal of Nuclear Medicine, 2016, 57, 777-784.}	2.8	197
184	Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano, 2016, 10, 4209-4218.	7.3	103
185	PET imaging evaluation of [18F]DBT-10, a novel radioligand specific to α7 nicotinic acetylcholine receptors, in nonhuman primates. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 537-547.	3.3	20
186	Abdominal multi-organ segmentation of dynamic PET studies using modified fuzzy clustering algorithm. , $2015, \ldots$		2
187	P3-143: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first-degree relatives at varying ApoE4 risk for Alzheimer's disease. , 2015, 11, P680-P681.		0
188	Further evaluation of [11C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis. Synapse, 2015, 69, 86-95.	0.6	18
189	Assessment of kinetic modeling quality of fit by cluster analysis of residuals: Application to direct reconstruction of cardiac PET data., 2015,,.		3
190	Test–Retest Reproducibility of Binding Parameters in Humans with ¹¹ C-LY2795050, an Antagonist PET Radiotracer for the κ Opioid Receptor. Journal of Nuclear Medicine, 2015, 56, 243-248.	2.8	35
191	IC-P-101: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first-degree relatives at varying ApoE4 risk for Alzheimer's disease. , 2015, 11, P69-P69.		0
192	In Vivo Ketamine-Induced Changes in [11 C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. Biological Psychiatry, 2015, 77, 266-275.	0.7	82
193	Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia. JAMA Psychiatry, 2015, 72, 316.	6.0	304
194	Evaluation of [$18F$]-(-)-norchlorofluorohomoepibatidine ([$18F$]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates. Nuclear Medicine and Biology, $2015, 42, 570-577$.	0.3	17
195	Imaging human brown adipose tissue under room temperature conditions with 11C-MRB, a selective norepinephrine transporter PET ligand. Metabolism: Clinical and Experimental, 2015, 64, 747-755.	1.5	25
196	Test–retest reliability of the novel 5-HT1B receptor PET radioligand [11C]P943. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 468-477.	3.3	20
197	11C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1081-1092.	3. 3	77
198	Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12468-12473.	3. 3	265

#	Article	IF	CITATIONS
199	Measurement of <i>B</i> _{max} and <i>K</i> _d with the Glycine Transporter 1 Radiotracer ¹⁸ F-MK6577 using a Novel Multi-Infusion Paradigm. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 2001-2009.	2.4	10
200	Imaging the Cannabinoid CB1 Receptor in Humans with [¹¹ C] OMAR: Assessment of Kinetic Analysis Methods, Test–Retest Reproducibility, and Gender Differences. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1313-1322.	2.4	79
201	Test–retest reproducibility of the metabotropic glutamate receptor 5 ligand [18F]FPEB with bolus plus constant infusion in humans. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1530-1541.	3.3	37
202	A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [11C](+)PHNO. Drug and Alcohol Dependence, 2015, 154, 167-173.	1.6	25
203	Tobacco smoking interferes with GABA _A receptor neuroadaptations during prolonged alcohol withdrawal. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18031-18036.	3.3	21
204	Association of In Vivo \hat{I}^2 -Opioid Receptor Availability and the Transdiagnostic Dimensional Expression of Trauma-Related Psychopathology. JAMA Psychiatry, 2014, 71, 1262.	6.0	67
205	Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus Monkeys with [11C]PHNO vs [11C]raclopride PET. Neuropsychopharmacology, 2014, 39, 866-874.	2.8	43
206	Radiolabeling of Poly(lactic- <i>co</i> -glycolic acid) (PLGA) Nanoparticles with Biotinylated F-18 Prosthetic Groups and Imaging of Their Delivery to the Brain with Positron Emission Tomography. Bioconjugate Chemistry, 2014, 25, 2157-2165.	1.8	45
207	Evaluation of the sensitivity of the novel α4β2* nicotinic acetylcholine receptor PET radioligand ¹⁸ Fâ€(â€)â€NCFHEB to increases in synaptic acetylcholine levels in rhesus monkeys. Synapse, 2014, 68, 556-564.	0.6	21
208	Kinetic Modeling of 11C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in Humans. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1818-1825.	2.4	42
209	An Improved Antagonist Radiotracer for the \hat{I}^2 -Opioid Receptor: Synthesis and Characterization of 11C-LY2459989. Journal of Nuclear Medicine, 2014, 55, 1185-1191.	2.8	26
210	Evaluation of ¹¹ C-BU99008, a PET Ligand for the Imidazoline ₂ Binding Sites in Rhesus Brain. Journal of Nuclear Medicine, 2014, 55, 838-844.	2.8	44
211	Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. Journal of Nuclear Medicine, 2014, 55, 595-601.	2.8	50
212	Biodistribution and Radiation Dosimetry of LMI1195: First-in-Human Study of a Novel ¹⁸ F-Labeled Tracer for Imaging Myocardial Innervation. Journal of Nuclear Medicine, 2014, 55, 1445-1451.	2.8	91
213	Evaluation of Frame-Based and Event-by-Event Motion-Correction Methods for Awake Monkey Brain PET Imaging. Journal of Nuclear Medicine, 2014, 55, 287-293.	2.8	12
214	Imaging Glutamate Homeostasis in Cocaine Addiction with the Metabotropic Glutamate Receptor 5 Positron Emission Tomography Radiotracer [11C]ABP688 and Magnetic Resonance Spectroscopy. Biological Psychiatry, 2014, 75, 165-171.	0.7	66
215	Dopamine D3 receptor alterations in cocaine-dependent humans imaged with [11C](+)PHNO. Drug and Alcohol Dependence, 2014, 139, 100-105.	1.6	63
216	Reductions in Brain 5-HT1B Receptor Availability in Primarily Cocaine-Dependent Humans. Biological Psychiatry, 2014, 76, 816-822.	0.7	50

#	Article	IF	Citations
217	Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[11C]O-methylreboxetine. NeuroImage, 2014, 86, 306-310.	2.1	41
218	Parametric Imaging and Testâ€"Retest Variability of ¹¹ C-(+)-PHNO Binding to D ₂ /D ₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner. Journal of Nuclear Medicine, 2014, 55, 960-966.	2.8	38
219	Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242. Neurolmage, 2014, 99, 69-79.	2.1	54
220	Direct EM reconstruction of kinetic parameters from list-mode cardiac PET., 2014, , .		9
221	Data-driven respiratory motion estimation and correction using TOF PET list-mode centroid of distribution. , 2014, , .		3
222	The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study. Brain, Behavior, and Immunity, 2013, 33, 131-138.	2.0	180
223	Direct, Quantitative, and Noninvasive Imaging of the Transport of Active Agents Through Intact Brain with Positron Emission Tomography. Molecular Imaging and Biology, 2013, 15, 596-605.	1.3	4
224	Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression. European Neuropsychopharmacology, 2013, 23, 822-829.	0.3	30
225	Association of Posttraumatic Stress Disorder With Reduced In Vivo Norepinephrine Transporter Availability in the Locus Coeruleus. JAMA Psychiatry, 2013, 70, 1199.	6.0	116
226	Studies of the metabotropic glutamate receptor 5 radioligand [$\sup 11 < \sup C$]ABP688 with $\le N < \sup C$].	0.6	42
227	Feasible uniform-resolution penalized likelihood reconstruction for static- and multi-frame 3D PET. , 2013, , .		0
228	Effect of subsets on bias and variance in low-count iterative PET reconstruction. , 2013, , .		1
229	List-Mode PET Motion Correction Using Markerless Head Tracking: Proof-of-Concept With Scans of Human Subject. IEEE Transactions on Medical Imaging, 2013, 32, 200-209.	5.4	55
230	In Hot Blood. JACC: Cardiovascular Imaging, 2013, 6, 569-573.	2.3	17
231	Synthesis and Evaluation of 11C-LY2795050 as a \hat{I}^2 -Opioid Receptor Antagonist Radiotracer for PET Imaging. Journal of Nuclear Medicine, 2013, 54, 455-463.	2.8	80
232	Kinetic Analysis of Drug–Target Interactions with PET for Characterization of Pharmacological Hysteresis. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 700-707.	2.4	13
233	Optimization of PET–MR registrations for nonhuman primates using mutual information measures: A Multi-Transform Method (MTM). Neurolmage, 2013, 64, 571-581.	2.1	26
234	List-mode reconstruction for the Biograph mCT with physics modeling and event-by-event motion correction. Physics in Medicine and Biology, 2013, 58, 5567-5591.	1.6	47

#	Article	IF	CITATIONS
235	Eventâ€byâ€event respiratory motion correction for PET with 3D internalâ€1D external motion correlation. Medical Physics, 2013, 40, 112507.	1.6	27
236	Determination of the In Vivo Selectivity of a New κ-Opioid Receptor Antagonist PET Tracer ¹¹ C-LY2795050 in the Rhesus Monkey. Journal of Nuclear Medicine, 2013, 54, 1668-1674.	2.8	34
237	Tracer Kinetic Modeling of [$<$ sup $>$ 11 $<$ /sup $>$ C]AFM, a New PET Imaging Agent for the Serotonin Transporter. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1886-1896.	2.4	17
238	Awake Nonhuman Primate Brain PET Imaging with Minimal Head Restraint: Evaluation of GABA _A -Benzodiazepine Binding with ¹¹ C-Flumazenil in Awake and Anesthetized Animals. Journal of Nuclear Medicine, 2013, 54, 1962-1968.	2.8	19
239	Imaging Changes in Synaptic Acetylcholine Availability in Living Human Subjects. Journal of Nuclear Medicine, 2013, 54, 78-82.	2.8	33
240	Determination of In Vivo <i>B</i> _{max} and <i>K</i> _d for ¹¹ C-GR103545, an Agonist PET Tracer for κ-Opioid Receptors: A Study in Nonhuman Primates. Journal of Nuclear Medicine, 2013, 54, 600-608.	2.8	31
241	Cerebral blood flow with [¹⁵ O]water PET studies using an image-derived input function and MR-defined carotid centerlines. Physics in Medicine and Biology, 2013, 58, 1903-1923.	1.6	51
242	Kinetic Analysis of the Metabotropic Glutamate Subtype 5 Tracer [¹⁸ F]FPEB in Bolus and Bolus-Plus-Constant-Infusion Studies in Humans. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 532-541.	2.4	61
243	Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11751-11756.	3.3	222
244	Evaluation of motion correction methods in human brain PET imaging—A simulation study based on human motion data. Medical Physics, 2013, 40, 102503.	1.6	83
245	Test-retest reproducibility of [11C]-(+)-propyl-hexahydro-naphtho-oxazin positron emission tomography using the bolus plus constant infusion paradigm. Molecular Imaging, 2013, 12, 77-82.	0.7	13
246	Event-by-event respiratory motion correction for PET with 3-Dimensional internal-external motion correlation. , $2012, \ldots$		5
247	Myocardial blood flow from dynamic PET using Independent Component Analysis. , 2012, , .		1
248	Uniform Spatial resolution list mode reconstruction for the HRRT. , 2012, , .		1
249	Yale Center for Clinical Investigation: Leveraging Industry Partnerships and Research Cores. Clinical and Translational Science, 2012, 5, 435-436.	1.5	0
250	List-mode reconstruction for the FOCUS-220 with motion correction and spatially-variant probability density functions: Application to awake monkey imaging. , 2012, , .		0
251	Dynamic assessment of head motion compensation for the HRRT. , 2012, , .		0
252	List-mode reconstruction for the Biograph mCT with probabilistic line-of-response positioning and event-by-event motion correction. , 2012 , , .		3

#	Article	IF	Citations
253	Assessment of a three-dimensional line-of-response probability density function system matrix for PET. Physics in Medicine and Biology, 2012, 57, 6827-6848.	1.6	18
254	Age Effects on Serotonin Receptor 1B as Assessed by PET. Journal of Nuclear Medicine, 2012, 53, 1411-1414.	2.8	26
255	Glucose Metabolism in the Insula and Cingulate Is Affected by Systemic Inflammation in Humans. Journal of Nuclear Medicine, 2012, 53, 601-607.	2.8	100
256	In Vivo Imaging of Endogenous Pancreatic \hat{l}^2 -Cell Mass in Healthy and Type 1 Diabetic Subjects Using ¹⁸ F-Fluoropropyl-Dihydrotetrabenazine and PET. Journal of Nuclear Medicine, 2012, 53, 908-916.	2.8	108
257	Direct 4-D PET List Mode Parametric Reconstruction With a Novel EM Algorithm. IEEE Transactions on Medical Imaging, 2012, 31, 2213-2223.	5.4	42
258	Widespread abnormality of the \hat{l}^3 -aminobutyric acid-ergic system in Tourette syndrome. Brain, 2012, 135, 1926-1936.	3.7	166
259	Positron Emission Tomography Shows Elevated Cannabinoid <scp>CB</scp> ₁ Receptor Binding in Men with Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2012, 36, 2104-2109.	1.4	53
260	Endotoxin-induced systemic inflammation activates microglia: [11C]PBR28 positron emission tomography in nonhuman primates. Neurolmage, 2012, 63, 232-239.	2.1	179
261	Ex Vivo and In Vivo Evaluation of the Norepinephrine Transporter Ligand [11C]MRB for Brown Adipose Tissue Imaging. Nuclear Medicine and Biology, 2012, 39, 1081-1086.	0.3	31
262	Affinity and selectivity of [¹¹ C]â€(+)â€PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse, 2012, 66, 489-500.	0.6	74
263	Reduced Amygdala Serotonin Transporter Binding in Posttraumatic Stress Disorder. Biological Psychiatry, 2011, 70, 1033-1038.	0.7	7 9
264	Evaluation of [11C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. NeuroImage, 2011, 56, 268-279.	2.1	50
265	Radiosynthesis and in vivo evaluation of [11C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nuclear Medicine and Biology, 2011, 38, 875-884.	0.3	42
266	Lateralization and gender differences in the dopaminergic response to unpredictable reward in the human ventral striatum. European Journal of Neuroscience, 2011, 33, 1706-1715.	1.2	82
267	Pancreatic Beta Cell Mass PET Imaging and Quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in Rodent Models of Diabetes. Molecular Imaging and Biology, 2011, 13, 973-984.	1.3	54
268	Assessing the sensitivity of [¹¹ C]p943, a novel 5â€HT _{IB} radioligand, to endogenous serotonin release. Synapse, 2011, 65, 1113-1117.	0.6	21
269	Recovery from chronic spinal cord contusion after nogo receptor intervention. Annals of Neurology, 2011, 70, 805-821.	2.8	87
270	Validation of the spatially variant probability density functions for the HRRT., 2011,,.		3

#	Article	IF	Citations
271	The Effect of Early Trauma Exposure on Serotonin Type 1B Receptor Expression Revealed by Reduced Selective Radioligand Binding. Archives of General Psychiatry, 2011, 68, 892.	13.8	84
272	Arterial transit time effects in pulsed arterial spin labeling CBF mapping: Insight from a PET and MR study in normal human subjects. Magnetic Resonance in Medicine, 2010, 63, 374-384.	1.9	58
273	PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[¹¹ C]O-methylreboxetine and HRRT. Synapse, 2010, 64, 30-38.	0.6	112
274	Kinetic Modeling of the Serotonin 5-HT _{1B} Receptor Radioligand [¹¹ C]P943 in Humans. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 196-210.	2.4	83
275	Quantification of Smoking-Induced Occupancy of \hat{l}^2 2-Nicotinic Acetylcholine Receptors: Estimation of Nondisplaceable Binding. Journal of Nuclear Medicine, 2010, 51, 1226-1233.	2.8	33
276	Multiple acquisition frame-based motion correction for awake monkey PET imaging. , 2010, , .		2
277	Evaluation of direct 4D parametric reconstruction with low count human PET data., 2010,,.		1
278	Segmentation of rat spinal cord in PET using spatiotemporal information. , 2010, , .		0
279	Count-rate dependent resolution degradation from pulse pile-up on the HRRT. , 2010, , .		6
280	Evaluation of a 3D point spread function (PSF) model derived from Monte Carlo simulation for a small animal PET scanner. Proceedings of SPIE, 2010, , .	0.8	0
281	Serotonin 1B Receptor Imaging in Alcohol Dependence. Biological Psychiatry, 2010, 67, 800-803.	0.7	69
282	Effects of Early-Life Stress on Serotonin1A Receptors in Juvenile Rhesus Monkeys Measured by Positron Emission Tomography. Biological Psychiatry, 2010, 67, 1146-1153.	0.7	71
283	Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo. Biological Psychiatry, 2010, 68, 854-860.	0.7	201
284	PET evaluation of the TSPO ligands [F-18]FEPPA, [F-18]PRBO6, and [F-18]PBR111 in nonhuman primate. Neurolmage, 2010, 52, S147.	2.1	0
285	Kinetic modeling of the mGluR5 tracer [18F]F-FPEB in humans. NeuroImage, 2010, 52, S169-S170.	2.1	1
286	Kinetic analysis of the kappa agonist tracer [11C]GR103545 in healthy controls. NeuroImage, 2010, 52, S172.	2.1	2
287	Awake nonhuman primate brain PET imaging without head restraint. Neurolmage, 2010, 52, S18.	2.1	1
288	High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [11C]P943. Nuclear Medicine and Biology, 2010, 37, 205-214.	0.3	40

#	Article	IF	CITATIONS
289	Accuracy of head motion compensation for the HRRT: Comparison of methods., 2009, 2009, 3199-3202.		6
290	Initial evaluation of direct 4D parametric reconstruction with human PET data., 2009, 2009, 2503-2506.		7
291	A multimodal approach to image-derived input functions for brain PET. , 2009, 2009, 2710-2714.		12
292	Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. Journal of Lipid Research, 2009, 50, 1259-1268.	2.0	156
293	Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5056-5059.	1.0	24
294	Noninvasive Estimation of Normalized Distribution Volume: Application to the Muscarinic-2 Ligand [18F]FP-TZTP. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 420-430.	2.4	19
295	Imaging Neuroinflammation in Alzheimer's Disease with Radiolabeled Arachidonic Acid and PET. Journal of Nuclear Medicine, 2008, 49, 1414-1421.	2.8	158
296	Direct 4D list mode parametric reconstruction for PET with a novel EM algorithm., 2008, 4774103, 3625-3628.		19
297	Altered Cerebral γ-Aminobutyric Acid Type A–Benzodiazepine Receptor Binding in Panic Disorder Determined by [11C]Flumazenil Positron Emission Tomography. Archives of General Psychiatry, 2008, 65, 1166.	13.8	103
298	Quantitative accuracy of HRRT IIST-MODE reconstructions: Effect of low statistics. , 2008, 2008, 5121-5124.		13
299	Task-Related Interaction between Basal Ganglia and Cortical Dopamine Release. Journal of Neuroscience, 2007, 27, 14434-14441.	1.7	41
300	Imaging signal transduction via arachidonic acid in the human brain during visual stimulation, by means of positron emission tomography. NeuroImage, 2007, 34, 1342-1351.	2.1	39
301	Count-Rate Dependent Component-Based Normalization for the HRRT. IEEE Transactions on Nuclear Science, 2007, 54, 486-495.	1.2	22
302	Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1533-1539.	2.4	1,840
303	Consensus nomenclature: its time has come. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1239-1239.	3.3	10
304	Cerebral blood flow in temporal lobe epilepsy: a partial volume correction study. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 2066-2072.	3.3	6
305	Long-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC. Molecular Therapy, 2006, 14, 564-570.	3.7	249
306	Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects. Journal of Clinical Psychopharmacology, 2006, 26, 595-599.	0.7	12

#	Article	IF	Citations
307	Reduced Muscarinic Type 2 Receptor Binding in Subjects With Bipolar Disorder. Archives of General Psychiatry, 2006, 63, 741.	13.8	106
308	Age and APOE- $\hat{l}\mu 4$ genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP. Synapse, 2006, 60, 86-92.	0.6	18
309	The Effect of Antiepileptic Drugs on 5-HT1A-Receptor Binding Measured by Positron Emission Tomography. Epilepsia, 2006, 47, 499-503.	2.6	57
310	Measurement of Regional Rates of Cerebral Protein Synthesis with L-[1-11C]leucine and PET with Correction for Recycling of Tissue Amino Acids: II. Validation in Rhesus Monkeys. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 629-640.	2.4	42
311	No Change in Serotonin Type 1A Receptor Binding in Patients With Posttraumatic Stress Disorder. American Journal of Psychiatry, 2005, 162, 383-385.	4.0	70
312	Tracer Kinetic Modeling in PET., 2005, , 127-159.		91
313	Differential effects of paroxetine on raphe and cortical 5-HT1A binding: A PET study in monkeys. Neurolmage, 2005, 28, 238-248.	2.1	27
314	5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. Journal of Nuclear Medicine, 2005, 46, 1128-35.	2.8	92
315	Nicotine-Induced Dopamine Release in Primates Measured with [11C]Raclopride PET. Neuropsychopharmacology, 2004, 29, 259-268.	2.8	57
316	Reduced Serotonin Type 1A Receptor Binding in Panic Disorder. Journal of Neuroscience, 2004, 24, 589-591.	1.7	350
317	Toward an evolutionary perspective on conceptual representation: Species-specific calls activate visual and affective processing systems in the macaque. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17516-17521.	3.3	118
318	Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 18171-18176.	3.3	334
319	A Potential Cholinergic Mechanism of Procaine's Limbic Activation. Neuropsychopharmacology, 2004, 29, 1239-1250.	2.8	23
320	Species-specific calls evoke asymmetric activity in the monkey's temporal poles. Nature, 2004, 427, 448-451.	13.7	324
321	Brain incorporation of $11C$ -arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. Journal of Nuclear Medicine, 2004, 45, 1471-9.	2.8	76
322	In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse, 2003, 48, 39-44.	0.6	64
323	Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-?4 allele. Synapse, 2003, 49, 150-156.	0.6	59
324	Brain Uptake of the Acid Metabolites of F-18â€"Labeled WAY 100635 Analogs. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 249-260.	2.4	44

#	Article	IF	Citations
325	Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1096-1112.	2.4	574
326	Determination of [18F]FCWAY, [18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions. Nuclear Medicine and Biology, 2003, 30, 233-240.	0.3	23
327	Brain Uptake of the Acid Metabolites of F-18???Labeled WAY 100635 Analogs. Journal of Cerebral Blood Flow and Metabolism, 2003, , 249-260.	2.4	19
328	Brain Incorporation of [¹¹ C]Arachidonic Acid in Young Healthy Humans Measured with Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1453-1462.	2.4	63
329	Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1440-1452.	2.4	353
330	Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1271-1281.	2.4	286
331	Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neuroscience, 2002, 5, 267-271.	7.1	603
332	Scatchard Analysis with Bolus/Infusion Administration of [11C]Raclopride., 2002,, 63-69.		3
333	Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1271-1281.	2.4	84
334	Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1440-1452.	2.4	110
335	Brain Incorporation of [11C]Arachidonic Acid in Young Healthy Humans Measured With Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1453-1462.	2.4	27
336	Device-dependent activity estimation and decay correction of radionuclide mixtures with application to Tc-94m PET studies. Medical Physics, 2001, 28, 36-45.	1.6	12
337	Amphetamine-Induced Dopamine Release., 2001,, 205-209.		12
338	[α-11C]Methyl-l-tryptophan in Anesthetized Rhesus Monkeys. , 2001, , 229-235.		1
339	Opiate receptor avidity in the thalamus is sexually dimorphic in the elderly. Synapse, 2000, 38, 226-229.	0.6	13
340	Synthesis and evaluation of an 18F analog of forskolin for imaging adenylyl cyclase. Journal of Fluorine Chemistry, 2000, 101, 297-304.	0.9	13
341	The Suitability of $[11C]$ - \hat{l} ±-Methyl-L-tryptophan as a Tracer for Serotonin Synthesis: Studies With Dual Administration of $[11C]$ and $[14C]$ Labeled Tracer. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 244-252.	2.4	74
342	Kinetic Analysis of the 5-HT2A Ligand [11C]MDL 100,907. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 899-909.	2.4	78

#	Article	IF	CITATIONS
343	Opiate receptor avidity is increased in rhesus monkeys following unilateral optic tract lesion combined with transections of corpus callosum and hippocampal and anterior commissures. Brain Research, 2000, 879, 1-6.	1.1	4
344	PET evaluation of [18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nuclear Medicine and Biology, 2000, 27, 493-497.	0.3	71
345	Pet physiological measurements using constant infusion. Nuclear Medicine and Biology, 2000, 27, 657-660.	0.3	83
346	Comparison of PET [150]Water Studies with 6-Minute and 10-Minute InterScan Intervals: Single-Subject and Group Analyses. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 570-582.	2.4	17
347	Bolus Injection versus Slow Infusion of [150]Water for Positron Emission Tomography Activation Studies. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 843-852.	2.4	9
348	In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazolyl tetrahydropyridines. Synapse, 1999, 31, 29-40.	0.6	30
349	Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP., 1999, 33, 282-288.		10
350	Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Life Sciences, 1999, 64, 511-518.	2.0	12
351	Development of Fluorine-18-Labeled 5-HT1AAntagonists. Journal of Medicinal Chemistry, 1999, 42, 1576-1586.	2.9	112
352	Positron Emission Tomography [150]Water Studies with Short InterScan Interval for Single-Subject and Group Analysis: Influence of Background Subtraction. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 433-444.	2.4	18
353	Muscarinic Cholinergic Receptor Measurements with [18F]FP-TZTP: Control and Competition Studies. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 1130-1142.	2.4	98
354	Assessment of Dynamic Neurotransmitter Changes with Bolus or Infusion Delivery of Neuroreceptor Ligands. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 1196-1210.	2.4	72
355	Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys. Brain Research, 1998, 806, 292-296.	1.1	15
356	Brain Serotonin Synthesis Rates in Rhesus Monkeys Determined by $[11C]\hat{I}\pm$ -Methyl-?-Tryptophan and Positron Emission Tomography Compared to CSF 5-Hydroxyindole-3-Acetic Acid Concentrations. Neuropsychopharmacology, 1998, 19, 345-353.	2.8	37
357	Dissociated Pattern of Activity in Visual Cortices and Their Projections During Human Rapid Eye Movement Sleep. Science, 1998, 279, 91-95.	6.0	584
358	Axial slice width in 3D PET: characterization and potential improvement with axial interleaving. Physics in Medicine and Biology, 1998, 43, 921-928.	1.6	5
359	Characteristics of Neurotransmitter Competition Studies Using Constant Infusion of Tracer 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII, 1998,, 435-439.		0
360	Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. Journal of the Neurological Sciences, 1997, 148, 171-180.	0.3	47

#	Article	IF	Citations
361	In vivo muscarinic binding selectivity of QNB. Bioorganic and Medicinal Chemistry, 1997, 5, 1555-1567.	1.4	17
362	Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 437-447.	2.4	237
363	Optimization of Noninvasive Activation Studies with 150-Water and Three-Dimensional Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 732-739.	2.4	22
364	Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 932-942.	2.4	183
365	Quantification and pharmacokinetics of blood-brain barrier disruption in humans. Journal of Neurosurgery, 1996, 85, 1056-1065.	0.9	98
366	Hyperosmolar blood-brain barrier disruption in baboons: an in vivo study using positron emission tomography and rubidium-82. Journal of Neurosurgery, 1996, 84, 494-502.	0.9	26
367	Absolute Cerebral Blood Flow with [150]Water and PET. , 1996, , 185-190.		7
368	The Functional Neuroanatomy of Tourette's Syndrome: An FDG-PET Study. II: Relationships between Regional Cerebral Metabolism and Associated Behavioral and Cognitive Features of the Illness. Neuropsychopharmacology, 1995, 13, 151-168.	2.8	75
369	A kinetic comparison of [18F]2-fluoro-2-deoxyglucose and [18F]2-fluoro-2-deoxymannose using positron emission tomography. Nuclear Medicine and Biology, 1994, 21, 857-863.	0.3	5
370	Analysis of Covariance in Statistical Parametric Mapping. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 1038-1038.	2.4	11
371	Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [¹⁸ F]Cyclofoxy and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 24-42.	2.4	343
372	Reproducibility of Resting Cerebral Blood Flow Measurements with H ₂ ¹⁵ O Positron Emission Tomography in Humans. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 748-754.	2.4	75
373	Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. Neurobiology of Aging, 1993, 14, 35-44.	1.5	103
374	The Functional Neuroanatomy of Tourette's Syndrome: An FDG-PET Study. I. Regional Changes in Cerebral Glucose Metabolism Differentiating Patients and Controls. Neuropsychopharmacology, 1993, 9, 277-291.	2.8	166
375	Dissociation of Object and Spatial Vision in Human Extrastriate Cortex: Age-Related Changes in Activation of Regional Cerebral Blood Flow Measured with [15 O]Water and Positron Emission Tomography. Journal of Cognitive Neuroscience, 1992, 4, 23-34.	1.1	140
376	PET imaging of opiate receptor binding in human epilepsy using [18F]cyclofoxy. Epilepsy Research, 1992, 13, 129-139.	0.8	68
377	Distribution and Kinetics of 3-O-Methyl-6-[18F]fluoro-L-DOPA in the Rhesus Monkey Brain. Journal of Cerebral Blood Flow and Metabolism, 1991, 11, 726-734.	2.4	49
378	Precision and Accuracy Considerations of Physiological Quantitation in PET. Journal of Cerebral Blood Flow and Metabolism, 1991, 11, A45-A50.	2.4	34

#	Article	IF	Citations
379	Intravascular streaming during carotid artery infusions. Journal of Neurosurgery, 1991, 74, 763-772.	0.9	59
380	Brain Glucose Metabolism in Noninsulin-Dependent Diabetes Mellitus: A Study in Pima Indians Using Positron Emission Tomography during Hyperinsulinemia with Euglycemic Glucose Clamp. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 1602-1610.	1.8	32
381	A Realistic Computer-Simulated Brain Phantom for Evaluation of PET Charactenstics. IEEE Transactions on Medical Imaging, 1987, 6, 250-257.	5.4	12
382	Examination of Blood — Brain Barrier Permeability in Dementia of the Alzheimer Type with [⁶⁸ Ga]EDTA and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 1-8.	2.4	129
383	III. Biomathematical Aspects of Physiological Brain Imaging. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, S11-S13.	2.4	3
384	A Maximum Likelihood Method for Region-of-Interest Evaluation in Emission Tomography. Journal of Computer Assisted Tomography, 1986, 10, 654-663.	0.5	96
385	Weighted Integration Method for Local Cerebral Blood Flow Measurements with Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1986, 6, 245-258.	2.4	106
386	A Noninvasive Positron Computed Tomography Technique Using Oxygen-15-Labeled Water for the Evaluation of Neurobehavioral Task Batteries. Journal of Cerebral Blood Flow and Metabolism, 1985, 5, 70-78.	2.4	171
387	An Efficient Algorithm for Reconsiruction of SPECT Images in the Presence of Spatially Varying Attenuation. IEEE Transactions on Nuclear Science, 1985, 32, 1190-1197.	1.2	1
388	Theoretical Analysis of Optimal Conditions in Fquilibrium Imaging of in Vivo Receptors. IEEE Transactions on Nuclear Science, 1985, 32, 1496-1502.	1.2	2
389	Comment: The EM Parametric Image Reconstruction Algorithm. Journal of the American Statistical Association, 1985, 80, 20-22.	1.8	79
390	A Statistical Model for Positron Emission Tomography: Comment. Journal of the American Statistical Association, 1985, 80, 20.	1.8	42
391	Multiple-Radionuclide Autoradiography in Evaluation of Cerebral Function. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 264-269.	2.4	31
392	Cerebral Glucose Metabolism as a Function of Age in Man: Influence of the Rate Constants in the Fluorodeoxyglucose Method. Journal of Cerebral Blood Flow and Metabolism, 1983, 3, 250-253.	2.4	75
393	Tracer Kinetic Modeling in Positron Computed Tomography. Lecture Notes in Biomathematics, 1983, , 298-344.	0.3	2
394	All Analysis of Signal Amplification Using Small Detectors in Positron Emission Tomography. Journal of Computer Assisted Tomography, 1982, 6, 551-565.	0.5	80
395	Tomographic mapping of human cerebral metabolism: Sensory deprivation. Annals of Neurology, 1982, 12, 435-444.	2.8	127
396	Measurement of Local Blood Flow and Distribution Volume with Short-Lived Isotopes: A General Input Technique. Journal of Cerebral Blood Flow and Metabolism, 1982, 2, 99-108.	2.4	123